{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:00:21Z","timestamp":1790456421080,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019657","name":"CardioVascular Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019657","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Asia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacasi.2026.08.016","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:38:25Z","timestamp":1790368705000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Impact of Lipoprotein(a) on Cardiovascular Outcomes Across Coronary Complexity in Patients Undergoing Coronary Revascularization"],"prefix":"10.1016","author":[{"given":"Hoyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8484-238X","authenticated-orcid":false,"given":"Jung-Min","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Yoon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Bong","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Yeon","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5123-8383","authenticated-orcid":false,"given":"Han Su","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4193-0891","authenticated-orcid":false,"given":"Ju Hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ah-Ram","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6643-0239","authenticated-orcid":false,"given":"Duk-Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Hak","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hoon","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Jung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacasi.2026.08.016_bib1","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2026.08.016_bib2","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2026.08.016_bib3","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacasi.2026.08.016_bib4","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.016_bib5","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacasi.2026.08.016_bib6","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.124.069210","article-title":"Lipoprotein(a) as a pharmacological target: premises, promises, and prospects","volume":"151","author":"Greco","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.08.016_bib7","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacasi.2026.08.016_bib8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2026.08.016_bib9","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.016_bib10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(18)30423-9","article-title":"Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data","volume":"391","author":"Head","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2026.08.016_bib11","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa0801441","article-title":"Stents versus coronary-artery bypass grafting for left main coronary artery disease","volume":"358","author":"Seung","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.016_bib12","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1161\/CIRCULATIONAHA.107.750109","article-title":"Long-term mortality after percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass surgery for the treatment of multivessel coronary artery disease","volume":"117","author":"Park","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.08.016_bib13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa071804","article-title":"Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease","volume":"358","author":"Hannan","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.016_bib14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2307\/2531402","article-title":"Approximate case influence for the proportional hazards regression model with censored data","volume":"40","author":"Cain","year":"1984","journal-title":"Biometrics"},{"key":"10.1016\/j.jacasi.2026.08.016_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen city heart study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.08.016_bib16","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2026.08.016_bib17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.016_bib18","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.jacc.2023.10.009","article-title":"Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, and major adverse limb events","volume":"82","author":"Thomas","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.016_bib19","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk","volume":"79","author":"Mehta","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.016_bib20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamacardio.2023.5605","article-title":"Lipoprotein(a), C-Reactive protein, and cardiovascular risk in primary and secondary prevention populations","volume":"9","author":"Small","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.016_bib21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacasi.2026.08.016_bib22","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.025397","article-title":"Lipoprotein(a) and the risk for coronary heart disease and ischemic stroke events among black and white adults with cardiovascular disease","volume":"11","author":"Colantonio","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacasi.2026.08.016_bib23","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.016_bib24","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.016_bib25","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.3390\/jcm13237109","article-title":"Lipoprotein(a) as an independent predictor of elevated SYNTAX score","volume":"13","author":"Kozie\u0142-Sio\u0142kowska","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacasi.2026.08.016_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/XCE.0000000000000327","article-title":"Cross-sectional study of lipoprotein(a) and the severity of coronary artery disease, cerebrovascular disease, and peripheral vascular disease in a group of South Asian patients","volume":"14","author":"Athauda-Arachchi","year":"2025","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"10.1016\/j.jacasi.2026.08.016_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2025.1470500","article-title":"Lipoproteins predicting coronary lesion complexity in premature coronary artery disease: a supervised machine learning approach","volume":"12","author":"Marcinkowska","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacasi.2026.08.016_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.102542","article-title":"Lipoprotein(a) and the early diagnosis, complexity, and extent of coronary artery disease and myocardial infarction","volume":"5","author":"Coerkamp","year":"2026","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacasi.2026.08.016_bib29","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jcin.2021.07.042","article-title":"Association of lipoprotein(a) with recurrent ischemic events following percutaneous coronary intervention","volume":"14","author":"Yoon","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacasi.2026.08.016_bib30","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3390\/molecules28030969","article-title":"Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment","volume":"28","author":"Lampsas","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.jacasi.2026.08.016_bib31","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.atherosclerosis.2013.01.014","article-title":"Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: meta-analysis of 9 cohort studies","volume":"227","author":"Qin","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacasi.2026.08.016_bib32","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCULATIONAHA.124.069556","article-title":"Independence of lipoprotein(a) and low-density lipoprotein cholesterol-mediated cardiovascular risk: a participant-level meta-analysis","volume":"151","author":"Bhatia","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.08.016_bib33","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.08.016_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.08.016_bib35","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.016_bib36","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.016_bib37","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran - a long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.08.016_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"}],"container-title":["JACC: Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374726007167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374726007167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:31:59Z","timestamp":1790454719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772374726007167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"alternative-id":["S2772374726007167"],"URL":"https:\/\/doi.org\/10.1016\/j.jacasi.2026.08.016","relation":{},"ISSN":["2772-3747"],"issn-type":[{"value":"2772-3747","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Impact of Lipoprotein(a) on Cardiovascular Outcomes Across Coronary Complexity in Patients Undergoing Coronary Revascularization","name":"articletitle","label":"Article Title"},{"value":"JACC: Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacasi.2026.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}